Cardiovascular Protection Using Beta-Blockers

Berenson, 2005 2003, 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension, J Hypertens, 21, 1011, 10.1097/00004872-200306000-00001 Chobanian, 2003, The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA, 289, 2560, 10.1001/jama.289.19.2560 Williams, 2004, British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary, BMJ, 328, 634, 10.1136/bmj.328.7440.634 Beevers, 2005, The end of beta blockers for uncomplicated hypertension?, Lancet, 366, 1510, 10.1016/S0140-6736(05)67575-7 1970, Effects of treatment on morbidity in hypertension, JAMA, 213, 1143 Messerli, 1998, Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?, JAMA, 279, 1903, 10.1001/jama.279.23.1903 1992, Medical Research Council trial of treatment of hypertension in older adults: principal results, BMJ, 304, 405, 10.1136/bmj.304.6824.405 Lever, 1993, MRC trial of treatment in elderly hypertensives, Clin Exp Hypertens, 15, 941, 10.3109/10641969309037083 Dahlof, 2005, Lancet, 366, 895, 10.1016/S0140-6736(05)67185-1 Collins, 1990, Blood pressure, stroke, and coronary heart disease, Lancet, 335, 827, 10.1016/0140-6736(90)90944-Z Bradley, 2006, How strong is the evidence for use of beta-blockers as first-line therapy for hypertension?, J Hypertens, 24, 2131, 10.1097/01.hjh.0000249685.58370.28 Carlberg, 2004, Atenolol in hypertension: is it a wise choice?, Lancet, 364, 1684, 10.1016/S0140-6736(04)17355-8 Khan, 2006, Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis, CMAJ, 174, 1737, 10.1503/cmaj.060110 Lindholm, 2005, Should beta blockers remain first choice in the treatment of primary hypertension?, Lancet, 366, 1545, 10.1016/S0140-6736(05)67573-3 Psaty, 2003, Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis, JAMA, 289, 2534, 10.1001/jama.289.19.2534 Turnbull, 2003, Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials, Lancet, 362, 1527, 10.1016/S0140-6736(03)14739-3 Wiysonge, 2007, Beta-blockers for hypertension, Cochrane Database Syst Rev, 10.1002/14651858.CD002003.pub2 Hansson, 1999, Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study, Lancet, 354, 1751, 10.1016/S0140-6736(99)10327-1 Black, 2003, Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial, JAMA, 289, 2073, 10.1001/jama.289.16.2073 Hansson, 2000, Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study, Lancet, 356, 359, 10.1016/S0140-6736(00)02526-5 Hansson, 1999, Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial, Lancet, 353, 611, 10.1016/S0140-6736(98)05012-0 Psaty, 1997, Health outcomes associated with antihypertensive therapies used as first-line agents, JAMA, 277, 739, 10.1001/jama.1997.03540330061036 Messerli, 2000, Antihypertensive therapy: beta-blockers and diuretics-why do physicians not always follow guidelines?, Proc Baylor Univ Med Center, 13, 128, 10.1080/08998280.2000.11927654 Dahlof, 1991, Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension), Lancet, 338, 1281, 10.1016/0140-6736(91)92589-T Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3 Hirata, 2005, Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial artery?, J Hypertens, 23, 551, 10.1097/01.hjh.0000160211.56103.48 Morgan, 2004, Effect of different antihypertensive drug classes on central aortic pressure, Am J Hypertens, 17, 118, 10.1016/j.amjhyper.2003.09.012 Williams, 2006, Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study, Circulation, 113, 1213, 10.1161/CIRCULATIONAHA.105.595496 Elliott, 2007, Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis, Lancet, 369, 201, 10.1016/S0140-6736(07)60108-1 Dunder, 2003, Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study, BMJ, 326, 681, 10.1136/bmj.326.7391.681 Davey, 2005, Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial, Ann Intern Med, 142, 313, 10.7326/0003-4819-142-5-200503010-00006 Alderman, 1999, Diabetes and cardiovascular events in hypertensive patients, Hypertension, 33, 1130, 10.1161/01.HYP.33.5.1130 Kostis, 2005, Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes, Am J Cardiol, 95, 29, 10.1016/j.amjcard.2004.08.059 Bakris, 2004, Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial, JAMA, 292, 2227, 10.1001/jama.292.18.2227 Lithell, 1991, Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism, Diabetes Care, 14, 203, 10.2337/diacare.14.3.203 Okin, 2004, Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events, JAMA, 292, 2343, 10.1001/jama.292.19.2343 Dahlof, 1992, Regression of left ventricular hypertrophy—a meta-analysis, Clin Exp Hypertens A, 14, 173 Ciulla, 2004, Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial, Circulation, 110, 552, 10.1161/01.CIR.0000137118.47943.5C Schiffrin, 2002, Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients, Am J Hypertens, 15, 105, 10.1016/S0895-7061(01)02290-7 Schiffrin, 2002, Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function, J Hypertens, 20, 71, 10.1097/00004872-200201000-00011 Schiffrin, 1994, Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension, Hypertension, 23, 83, 10.1161/01.HYP.23.1.83 Pischon, 2001, Use of beta-blockers in obesity hypertension: potential role of weight gain, Obes Rev, 2, 275, 10.1046/j.1467-789X.2001.00044.x Colditz, 1995, Weight gain as a risk factor for clinical diabetes mellitus in women, Ann Intern Med, 122, 481, 10.7326/0003-4819-122-7-199504010-00001 Messerli, 2007, Body weight changes with beta-blocker use: results from GEMINI, Am J Med, 120, 610, 10.1016/j.amjmed.2006.10.017 Donald, 1964, Effect of cardiac denervation on the maximal capacity for exercise in the racing Greyhound, J Appl Physiol, 19, 849, 10.1152/jappl.1964.19.5.849 Epstein, 1965, Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man, J Clin Invest, 44, 1745, 10.1172/JCI105282 Lim, 1996, Impaired exercise tolerance in hypertensive patients, Ann Intern Med, 124, 41, 10.7326/0003-4819-124-1_Part_1-199601010-00008 Turner, 1978, Comparative effect of nadolol and propranolol on exercise tolerance in patients with angina pectoris, Br Heart J, 40, 1361, 10.1136/hrt.40.12.1361 Messerli, 2002, Beta-blocker therapy and depression, JAMA, 288, 1845 Bangalore, 2007, Hypertension in the elderly: a compelling contraindication for beta-blockers?, J Hum Hypertens, 21, 259, 10.1038/sj.jhh.1002144 1999, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9 1999, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2 Packer, 2002, Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study, Circulation, 106, 2194, 10.1161/01.CIR.0000035653.72855.BF Brophy, 2001, Beta-blockers in congestive heart failure, Ann Intern Med, 134, 550, 10.7326/0003-4819-134-7-200104030-00008 Lechat, 1998, Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials, Circulation, 98, 1184, 10.1161/01.CIR.98.12.1184 Dulin, 2005, Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly?, Am J Cardiol, 95, 896, 10.1016/j.amjcard.2004.11.052 Shekelle, 2003, Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials, J Am Coll Cardiol, 41, 1529, 10.1016/S0735-1097(03)00262-6 Bell, 2006, The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis, Curr Med Res Opin, 22, 287, 10.1185/030079906X80459 Haas, 2003, Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure?, Am Heart J, 146, 848, 10.1016/S0002-8703(03)00403-4 Bouzamondo, 2003, Beta-blocker benefit according to severity of heart failure, Eur J Heart Fail, 5, 281, 10.1016/S1388-9842(03)00042-4 Krum, 2005, Prognostic benefit of beta-blockers in patients not receiving ACE-inhibitors, Eur Heart J, 26, 2154, 10.1093/eurheartj/ehi409 Hunt, 2001, Circulation, 104, 2996, 10.1161/hc4901.102568 Gibbons, 1999, J Am Coll Cardiol, 33, 2092, 10.1016/S0735-1097(99)00150-3 Opie, 2006, Controversies in cardiology, Lancet, 367, 13, 10.1016/S0140-6736(06)67903-8 Heidenreich, 1999, Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina, JAMA, 281, 1927, 10.1001/jama.281.20.1927 1985, Metoprolol in acute myocardial infarction (MIAMI), Eur Heart J, 6, 199, 10.1093/oxfordjournals.eurheartj.a061845 1986, Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1, Lancet, 2, 57 Roberts, 1991, Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction, Circulation, 83, 422, 10.1161/01.CIR.83.2.422 Pfisterer, 1998, Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience, J Am Coll Cardiol, 32, 634, 10.1016/S0735-1097(98)00279-4 Chen, 2005, Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet, 366, 1622, 10.1016/S0140-6736(05)67661-1 Yusuf, 1985, Beta blockade during and after myocardial infarction: an overview of the randomized trials, Prog Cardiovasc Dis, 27, 335, 10.1016/S0033-0620(85)80003-7 Gottlieb, 1998, Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction, N Engl J Med, 339, 489, 10.1056/NEJM199808203390801 Freemantle, 1999, Beta blockade after myocardial infarction: systematic review and meta regression analysis, BMJ, 318, 1730, 10.1136/bmj.318.7200.1730 Gislason, 2006, Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction, Eur Heart J, 27, 1153, 10.1093/eurheartj/ehi705 Bangalore, 2007, Verapamil-SR strategy is comparable to atenolol strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy, J Am Coll Cardiol, 49, 232A Schouten, 2006, A meta-analysis of safety and effectiveness of perioperative beta-blocker use for the prevention of cardiac events in different types of noncardiac surgery, Coron Artery Dis, 17, 173, 10.1097/00019501-200603000-00012 Fleisher, 2006, Circulation, 113, 2662, 10.1161/CIRCULATIONAHA.106.176009 Yang, 2006, The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial, Am Heart J, 152, 983, 10.1016/j.ahj.2006.07.024 McCullough, 2006, Failure of beta-blockers in the reduction of perioperative events: where did we go wrong?, Am Heart J, 152, 815, 10.1016/j.ahj.2006.08.006 Maron, 1997, Hypertrophic cardiomyopathy, Lancet, 350, 127, 10.1016/S0140-6736(97)01282-8 Gilligan, 1993, A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy, J Am Coll Cardiol, 21, 1672, 10.1016/0735-1097(93)90386-F Eliasch, 1967, Systemic circulatory response to stress of simulated flight and to physical exercise before and after propranolol blockade, Br Heart J, 29, 671, 10.1136/hrt.29.5.671 Taggart, 1973, Electrocardiogram, plasma catecholamines and lipids, and their modification by oxyprenolol when speaking before an audience, Lancet, 2, 341, 10.1016/S0140-6736(73)93190-5 Taggart, 1972, Suppression by oxprenolol of adrenergic response to stress, Lancet, 2, 256, 10.1016/S0140-6736(72)91689-3 Blomstrom-Lundqvist, 2003, Circulation, 108, 1871, 10.1161/01.CIR.0000091380.04100.84 Kaboli, 2007, Patient and provider perceptions of hypertension treatment: do they agree?, J Clin Hypertens, 9, 416, 10.1111/j.1524-6175.2007.06492.x 2006 Mancia, 2007, 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 28, 1462 Rosendorff, 2007, Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemilogy and Prevention, Circulation, 115, 2761, 10.1161/CIRCULATIONAHA.107.183885